Skip to main content
. 2014 Sep 3;5(20):9783–9797. doi: 10.18632/oncotarget.2392

Figure 1. Progesterone receptor expression is frequently downregulated with progression of endometrial cancer.

Figure 1

A, B PR protein (A), and PGR mRNA (B), expression was measured in endometrial tumors (n=5) and matched adjacent non-malignant tissue (n=5) by immunostaining and real-time PCR, respectively. Scale bar = 50 μm. Student's t-test was used for comparisons of two groups. (C) PGR mRNA expression was analyzed in 361 endometrial cancer patient tumors from TCGA database. Patients were divided into four groups: endometrioid type I grade 1 (G1, n=84), grade 2 (G2, n=100), grade 3 (G3, n=115) and serous Type II grade 3 (G3, n=62). Error bars, SEM. Statistical analysis was conducted using one way ANOVA with significance level set at α=0.05. All pairwise multiple comparisons were performed using Holm-Sidak method with Bonferroni correction. The results showed that all individual groups are significantly different from each other (p< 0.001) except between Type I G1 and Type I G2 (p=0.209).